难治性口腔扁平苔藓的免疫替代药物及作用机制研究进展  

Progress on Immune-replacement Drugs and Mechanisms of Action in Refractory Oral Lichen Planus

作　　者：余霜 周红梅[1] YU Shuang;ZHOU Hongmei(State Key Laboratory of Oral Diseases&National Center for Stomatology&National Clinical Research Center for Oral Diseases&Frontier Innovation Center for Dental Medicine Plus,Department of Oral Medicine,West China Hospital of Stomatology,Sichuan University,Chengdu 610041,China)

机构地区：[1]口腔疾病防治全国重点实验室,国家口腔医学中心,国家口腔疾病临床医学研究中心,口腔医学+前沿医学创新中心,四川大学华西口腔医院口腔黏膜病科,四川成都610041

出　　处：《口腔医学研究》2025年第1期7-11,共5页Journal of Oral Science Research

基　　金：国家自然科学基金面上项目(编号:82071124);“蓉城英才计划”医疗卫生领军人才项目(编号:20103)。

摘　　要：口腔扁平苔藓(oral lichen planus,OLP)是一种常见的口腔黏膜慢性炎性疾病,其发病机制主要涉及T细胞介导的抗原特异性免疫和非特异性免疫,糖皮质激素是国际公认的一线药物。对糖皮质激素抵抗或反应差的难治性OLP是临床管理的一大难点。由于局部免疫紊乱在难治性OLP的发生发展过程中发挥重要作用,因此探索有效且安全的免疫替代治疗药物成为近年研究热点。本文基于OLP的免疫发病机制,对常用免疫替代药物的临床应用和作用机制进行总结,并对潜在免疫替代药物作用靶点进行展望,旨在为难治性OLP的临床管理和未来研究提供参考。Oral lichen planus(OLP)is a common chronic inflammatory disease of the oral mucosa,with its pathogenesis primarily involving T-cell-mediated antigen-specific immunity and non-specific immunity,and glucocorticoids are internationally recognized as first-line drugs.Refractory OLP,which is resistant or poorly responsive to glucocorticoids,is a major difficulty in clinical management.Given the significant role of local immune disorders in the development of refractory OLP,exploring effective and safe immune-replacement drugs has become a hot research topic in recent years.This review summarizes the clinical applications and mechanisms of action of commonly used immune-replacement agents based on the immunopathogenesis of oral lichen planus,which offers insights into potential target of immune-replacement agents,aiming to provide a reference for the clinical management and future research of refractory OLP.

关 键 词：口腔扁平苔藓 难治性 免疫发病机制 免疫替代治疗药物 药物作用机制 

分 类 号：R781.5[医药卫生—口腔医学]